Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.,Journal of Antimicrobial Chemotherapy

当前位置： X-MOL 学术 › J. Antimicrob. Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2020-04-11 , DOI: 10.1093/jac/dkaa117
Mercedes Delgado-Valverde _{1,

2} , M Del Carmen Conejo ₃ , Lara Serrano ₁ , Felipe Fernández-Cuenca _{1,

2} , Álvaro Pascual _{1,

2,

3}

Affiliation

Cefiderocol is a novel siderophore cephalosporin, developed for activity against MDR Gram-negative bacilli (MDR-GNB).

中文翻译：